Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Action inhibitors |
Mechanism Aurora B inhibitors(Serine/threonine-protein kinase Aurora-B inhibitors), Aurora C inhibitors(Serine/threonine-protein kinase Aurora-C inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H33N7O |
InChIKeyQTBWCSQGBMPECM-UHFFFAOYSA-N |
CAS Registry942918-07-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | - | - | |
Ovarian Cancer | Preclinical | United States | - | - |
Non-Small Cell Lung Cancer | Discovery | United States | 14 Jul 2019 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Discovery | United States | 17 Jun 2019 | |
Acute Myeloid Leukemia | Discovery | United States | 03 Jun 2019 | |
Breast Cancer | Discovery | United States | 31 May 2019 | |
Solid tumor | Discovery | United Kingdom | 27 Nov 2015 | |
Advanced Malignant Solid Neoplasm | Discovery | United Kingdom | 01 Mar 2010 |
Phase 1 | 38 | (hutlplcicq) = snbwyuisph ollduhadko (kbxbbdmzob ) | - | 20 May 2013 |